(P< 0.05).ConclusionsThe FOLFOX-HAIC regimen in combination with nivolumab and lenvatinib is safe and effective for the treatment of intermediate and advanced HCC, without adverse reactions. It can prolong the overall survival and progression-free survival, and improve the patient′s quality of ...
1.Tintelnot, J., et al., Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO ...
Multicenter randomized phase II study of short course FOLFOX + nivolumab (Nivo) followed by maintenance Nivo +/- radiation (RT) in the first line treatment of metastatic or unresectable gastroesophageal adenocarcinoma (mGEA).doi:10.1200/JCO.2024.42.16_suppl.4060...
原始出处: Stein A, Paschold L, Tintelnot J, et al. Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO ...
Stein A, Paschold L, Tintelnot J, et al. Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial. JAMA Oncol. 2022 Jun 23. doi: 10.1001/jamaoncol....
Responses, Survival Outcomes in HER2+ Gastric/GEJ Cancer First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC Nivolumab Plus Chemo Shows Long-Term OS Benefit in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer View More Latest Confe...
2.Stein, A., et al., Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial. JAMA Oncology, 2022. ...
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma View LargeDownload Figure 1. CONSORT Diagram of the INTEGA Trial View LargeDownload Figure 2. Clinical Outcomes of Patients Treated in the ...
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17) 31046-2 15. Yau T, Hsu C, Kim TY, et al. Nivolumab in advanced ...
Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: The AIO INTEGA randomized clinical trial. JAMA Oncol. Published online:...